Literature DB >> 28898185

Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.

Mizuki Nishino1, Hiroto Hatabu1, Lynette M Sholl1, Nikhil H Ramaiya1.   

Abstract

Recent advances in understanding the molecular mechanisms of cancer have opened a new era of precision medicine for cancer treatment. Precision cancer therapies target specific molecules that are responsible for cancer development and progression, and they achieve marked treatment benefits in specific cohorts of patients. However, these therapies are also associated with a variety of complications that are often unique to specific groups of anticancer agents. The rapidly increasing use of immune checkpoint inhibitors in the treatment of various advanced malignancies has brought new challenges in diagnosing and monitoring a unique set of toxic effects termed immune-related adverse events. Familiarity with cutting-edge cancer treatment approaches and awareness of the emerging complications from novel therapies are essential for radiologists, who play a key role in the care of patients with cancer. This article provides a comprehensive review of the thoracic complications of precision cancer therapies, describes their imaging features and clinical characteristics, and discusses the role of radiologists in the diagnosis and monitoring of these entities. The authors also address the molecular mechanisms of anticancer agents that relate to thoracic complications and emphasize emerging challenges in novel cancer therapies. This article is designed to serve as a practical reference guide for day-to-day practice for radiologists in the era of precision cancer medicine. ©RSNA, 2017.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28898185      PMCID: PMC5621730          DOI: 10.1148/rg.2017170015

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  76 in total

1.  Pulmonary sarcoid-like granulomatosis induced by ipilimumab.

Authors:  Grégoire Berthod; Romain Lazor; Igor Letovanec; Emanuela Romano; Leslie Noirez; Jessica Mazza Stalder; Daniel E Speiser; Solange Peters; Olivier Michielin
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

Review 2.  Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment.

Authors:  Mizuki Nishino; Sree H Tirumani; Nikhil H Ramaiya; F Stephen Hodi
Journal:  Eur J Radiol       Date:  2015-03-23       Impact factor: 3.528

3.  Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.

Authors:  Jose Pablo Maroto; Gary Hudes; Janice P Dutcher; Theodore F Logan; Charles S White; Mizue Krygowski; Maria Cincotta; Mark Shapiro; Ignacio Duran; Anna Berkenblit
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

4.  Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors:  Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-11-19       Impact factor: 91.245

5.  Spontaneous bilateral pneumothorax in metastatic renal cell carcinoma on sunitinib therapy.

Authors:  Anilkumar Katta; Mark J Fesler; Alan Tan; Giao Vuong; John M Richart
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-05       Impact factor: 3.333

6.  Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma.

Authors:  V Gounant; S Brosseau; C Naltet; M-A Opsomer; M Antoine; C Danel; A Khalil; J Cadranel; G Zalcman
Journal:  Lung Cancer       Date:  2016-07-15       Impact factor: 5.705

Review 7.  Pulmonary complications of novel antineoplastic agents for solid tumors.

Authors:  Bobbak Vahid; Paul E Marik
Journal:  Chest       Date:  2008-02       Impact factor: 9.410

8.  High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy.

Authors:  M Kotake; H Murakami; H Kenmotsu; T Naito; T Takahashi
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

9.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Authors:  Pasi A Jänne; James Chih-Hsin Yang; Dong-Wan Kim; David Planchard; Yuichiro Ohe; Suresh S Ramalingam; Myung-Ju Ahn; Sang-We Kim; Wu-Chou Su; Leora Horn; Daniel Haggstrom; Enriqueta Felip; Joo-Hang Kim; Paul Frewer; Mireille Cantarini; Kathryn H Brown; Paul A Dickinson; Serban Ghiorghiu; Malcolm Ranson
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

Review 10.  Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.

Authors:  Claire F Friedman; Tracy A Proverbs-Singh; Michael A Postow
Journal:  JAMA Oncol       Date:  2016-10-01       Impact factor: 31.777

View more
  13 in total

1.  Managing Pulmonary Toxicities Associated with Immunotherapy: A Case Discussion.

Authors:  Vanessa A Reed; Naiyer Rizvi
Journal:  Oncologist       Date:  2019-03-21

2.  Radiographic patterns of symptomatic radiation pneumonitis in lung cancer patients: Imaging predictors for clinical severity and outcome.

Authors:  Richard Thomas; Yu-Hui Chen; Hiroto Hatabu; Raymond H Mak; Mizuki Nishino
Journal:  Lung Cancer       Date:  2020-04-30       Impact factor: 5.705

3.  Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors.

Authors:  Hyesun Park; Hiroto Hatabu; Biagio Ricciuti; Safiya J Aijazi; Mark M Awad; Mizuki Nishino
Journal:  Eur J Radiol       Date:  2020-09-10       Impact factor: 3.528

Review 4.  Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response.

Authors:  Minghao Wu; Yanyan Zhang; Yuwei Zhang; Ying Liu; Mingjie Wu; Zhaoxiang Ye
Journal:  Radiol Imaging Cancer       Date:  2019-11-29

Review 5.  Imaging of Cancer Immunotherapy: Current Approaches and Future Directions.

Authors:  Mizuki Nishino; Hiroto Hatabu; F Stephen Hodi
Journal:  Radiology       Date:  2018-11-20       Impact factor: 11.105

Review 6.  Imaging of Precision Therapy for Lung Cancer: Current State of the Art.

Authors:  Hyesun Park; Lynette M Sholl; Hiroto Hatabu; Mark M Awad; Mizuki Nishino
Journal:  Radiology       Date:  2019-08-06       Impact factor: 11.105

7.  Landscape of Immune-Related Pneumonitis in Cancer Patients with Asthma Being Treated with Immune Checkpoint Blockade.

Authors:  Jessica Galant-Swafford; Adrien Troesch; Lisa Tran; Ashley Weaver; Taylor A Doherty; Sandip Pravin Patel
Journal:  Oncology       Date:  2019-10-30       Impact factor: 2.935

Review 8.  Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.

Authors:  Konstantinos Melissaropoulos; Kalliopi Klavdianou; Alexandra Filippopoulou; Fotini Kalofonou; Haralabos Kalofonos; Dimitrios Daoussis
Journal:  Int J Mol Sci       Date:  2020-05-11       Impact factor: 5.923

9.  Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management.

Authors:  Jarushka Naidoo; Joshua E Reuss; Karthik Suresh; David Feller-Kopman; Patrick M Forde; Seema Mehta Steinke; Clare Rock; Douglas B Johnson; Mizuki Nishino; Julie R Brahmer
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

Review 10.  Differentiation of COVID-19 Pneumonitis and ICI Induced Pneumonitis.

Authors:  Daphne W Dumoulin; Hester A Gietema; Marthe S Paats; Lizza E L Hendriks; Robin Cornelissen
Journal:  Front Oncol       Date:  2020-10-29       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.